This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 01
  • /
  • Results from study of Grafalon (anti-human T-lymph...
Drug news

Results from study of Grafalon (anti-human T-lymphocyte globulin) in Graft versus host disease published in NEJM-Neovii

Read time: 1 mins
Last updated:17th Jan 2016
Published:17th Jan 2016
Source: Pharmawand

Results of a European study of Grafalon (anti-human T-lymphocyte globulin), from Neovii, in Graft versus host disease (GvHD), have been published in the January 2016 edition of the New England Journal of Medicine. The results showed at 2 years: the cumulative incidence of chronic GvHD was 32.2% in the study group with Grafalon compared to 68.7% in the non Grafalon group. The rate of the composite endpoint of chronic GvHD free and relapse free survival at 2 years was significantly higher in the Grafalon group than in the group without (36.6% vs 16.8%).

There were no significant differences between the groups in rates of relapse, infectious complications, acute GvHD, or adverse events. Prospective, multicenter, open-label, randomized, phase III study of Grafalon as part of a conditioning regimen prior to transplantation of allogeneic peripheral blood stem cells from HLA-identical siblings. The study was conducted in 27 European centres and enrolled 168 patients. Patients were randomized to either receive or not receive Grafalon.

See: Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.